title: Adjuvant Therapy for Salivary Gland Carcinomas.
abstract: OBJECTIVE
  We compared the clinical outcomes and toxicity profile among a retrospective cohort of patients with primary major salivary gland carcinomas (SGCs) treated with surgery followed by adjuvant radiation therapy (S+RT) versus surgery and adjuvant chemoradiotherapy (S+CRT).
  
  
  METHODS
  Twenty patients (71%) underwent S+RT and eight (29%) S+CRT at our Institution between 2006 and 2015. Microscopic positive margins were present in 54% of the patients.
  
  
  RESULTS
  The 3-year overall survival (OS) was 100% with S+RT and 87.5% with S+CRT (p=0.141) and locoregional control (LRC) was 95% with S+RT and 87.5% with S+CRT (p=0.383). There were no significant differences in the rate of acute (p=0.801) and late (p=0.714) toxicities.
  
  
  CONCLUSIONS
  While we await randomized data, adjuvant CRT may be considered as a viable therapeutic option for patients at high-risk of local or regional recurrence, especially in those with a positive microscopic margin where further surgery may result in functional cranial neuropathies.
authors.affiliation: University of Vermont, College of Medicine, Burlington, VT, U.S.A.
authors.forename: Mutlay
authors.initials: M
authors.lastname: Sayan
authors.affiliation: Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, U.S.A.
authors.forename: Prashant
authors.initials: P
authors.lastname: Vempati
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, U.S.A.
authors.forename: Brett
authors.initials: B
authors.lastname: Miles
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, U.S.A.
authors.forename: Marita
authors.initials: M
authors.lastname: Teng
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, U.S.A.
authors.forename: Eric
authors.initials: E
authors.lastname: Genden
authors.affiliation: Department of Pathology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, U.S.A.
authors.forename: Elizabeth G
authors.initials: EG
authors.lastname: Demicco
authors.affiliation: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, U.S.A.
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Misiukiewicz
authors.affiliation: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, U.S.A.
authors.forename: Marshall
authors.initials: M
authors.lastname: Posner
authors.affiliation: Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, U.S.A.
authors.forename: Vishal
authors.initials: V
authors.lastname: Gupta
authors.affiliation: Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, U.S.A. Richard.Bakst@mountsinai.org.
authors.forename: Richard L
authors.initials: RL
authors.lastname: Bakst
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003528:Carcinoma, Adenoid Cystic / Q000401:mortality / Q000628:therapy*; D059186:Chemoradiotherapy, Adjuvant; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012468:Salivary Gland Neoplasms / Q000401:mortality / Q000628:therapy*; D016896:Treatment Outcome
keywords: Salivary gland carcinoma; adjuvant therapy; chemoradiotherapy; radiotherapy